The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells. Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (DC m ), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not aect caspase-8 activation although it did change the processing pattern of caspase-3. At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9. Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of DC m . These ®ndings suggest that TRAILinduced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL or Apo2 ligand) was discovered as an apoptosis-inducing member of the TNF gene superfamily (Willey et al., 1995; Pitti et al., 1996) . TRAIL can interact with four cellular receptors but only two of them, DR4 (also called TRAIL-R1) and DR5 (TRAIL-R2, TRICK2, or KILLER) contain cytoplasmic death domains (DDs) and signal apoptosis (Pan et al., 1997a,b; Screaton et al., 1997; Sheridan et al., 1997; Walczak et al., 1997) . Analysis of the native TRAIL death-inducing signaling complex (DISC) revealed ligand-dependent recruitment of FADD (Fas-associated death domain protein) and caspase-8. Moreover, it has been shown that FADD and caspase-8 were recruited to TRAIL-R1 and -R2 independently of each other (Sprick et al., 2000) . It has also been shown that TRAIL recruits endogeneous FADD and caspase-8 to TRAIL-R1 and -R2 and can form both homomeric and heteromeric complexes with TRAIL-R1 and -R2 (Kischkel et al., 2000) . From these studies it was concluded that TRAIL utilizes a pathway similar to the one used by the Fas receptor.
The biochemical pathways of TRAIL-induced apoptosis have mainly been investigated in lymphoid cells. TRAIL-mediated apoptosis has been shown to involve activation of caspases -8 and -3, the late dissipation of the mitochondrial transmembrane potential (DC m ) and cytochrome c release. Overexpression of Bcl-2 in the human lymphoid cell line Jurkat did not protect against TRAIL-induced apoptosis. However, apoptosis induced by etoposide was decreased in these cells. These authors concluded that TRAIL induces apoptosis via a caspase cascade independent of the proapoptotic machinery of mitochondria . Similar results were found for lymphoid cell line CEM overexpressing Bcl-2 (Keogh et al., 2000) . Based on these and other data (Bonavida et al., 1999) it was suggested that TRAIL could be used as an antitumor agent in Bcl-2 overexpressing tumors since TRAIL can bypass the antiapoptotic eect of Bcl-2 overexpression .
Here we have characterized the biochemical pathway involved in TRAIL-induced apoptosis of prostatic carcinoma cells. The human prostatic carcinoma cell line PC3 is sensitive to Fas-mediated apoptosis, which occurs via activation of caspases -8 and -7, and involves cytochrome c release (Rokhlin et al., 1997 (Rokhlin et al., , 1998 Gewies et al., 2000) . Here we show that PC3 is sensitive to treatment with TRAIL that activates initiator caspases -2, -8, and -9, as well as executioner caspases -3 and -7, induces dissipation of DC m and caspase-dependent cytochrome c release. Bcl-2 overexpression did not aect caspase-8 activation, although it did change the processing pattern of caspase-3. At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9. Bcl-2 also abrogated TRAIL-induced dissipa-tion of DC m and cytochrome c release. These data suggest that, in contrast to lymphoid cells, TRAILinduced apoptosis in PC3 is dependent on mitochondrial integrity rather than on caspase activation.
Results

TRAIL-induced apoptosis is Bcl-2-dependent
We have previously shown that PC3 is sensitive to treatment with agonistic anti-Fas monoclonal antibodies and that the mitochondrial pathway is involved in Fas-mediated apoptosis (Rokhlin et al., 1997 (Rokhlin et al., , 1998 Gewies et al., 2000) . To determine the role of the mitochondrial pathway in TRAIL-mediated apoptosis, we overexpressed Bcl-2 in PC3 and then compared the pattern of apoptosis using PC3-Hygro (mock transfectant) and PC3-Bcl-2. As shown in Figure 1a , expression of Bcl-2 in PC3-Bcl-2 was found to be much higher compared to PC3-Hygro, especially in mitochondria. We then compared cell viability of these cell lines ( Figure 1b ) and found that PC3-Bcl-2 was signi®cantly more resistant to TRAIL-mediated cell death compared to PC3-Hygro. As can be seen from Figure 1b , 100 ng/ml of TRAIL killed more than 90% of PC3-Hygro cells after 24 h of treatment whereas only 25% of PC3-Bcl-2 cells were killed even by 1000 ng/ml of TRAIL. As expected, cell death of PC3 was found to be caspase-dependent since the pancaspase inhibitor Z-VAD-fmk completely prevented cell death under TRAIL treatment (Figure 1b) .
Cell death following TRAIL treatment is apoptotic based on the formation of a DNA ladder within 4 h of TRAIL treatment (data not shown) and the proteolysis of known caspase substrates (Utz and Anderson, 2000) . Both PARP and DFF45 are proteolyzed following TRAIL treatment and this can be blocked by Bcl-2 (Figure 2 ).
Bcl-2 overexpression does not affect caspase-8 activation but changes caspase-3 processing It has been reported that the initiator caspase-8 plays a crucial role in Fas-and TRAIL-mediated apoptosis and that the executioner caspase-3 is responsible for proteolysis of multiple targets during apoptosis induced by dierent agents (Utz and Anderson, 2000) . Surprisingly, we did not ®nd signi®cant dierences between PC3-Hygro and PC3-Bcl-2 in the activation pattern of caspase-8 after treatment with TRAIL. As can be seen from Figure 3 , caspase-8 was already activated after 20 min of treatment with TRAIL and to the same extent in both cell lines. However, caspase-3 was found to be underprocessed in PC3-Bcl-2; the weak activation band was observed after 1 h of treatment with TRAIL and this band disappeared after 4 h whereas in PC3-Hygro the caspase-3 activation band was detected at the same level as after 1 h of treatment. We have also examined the presence of caspases -8 and -3 in mitochondria and Figure 1 (a) Expression of Bcl-2 in PC3-Hygro and PC3-Bcl-2 transfectants. Expression of Bcl-2 was investigated by Western blot analysis. To analyse total cytosolic proteins, cells were harvested and lysed in 1% Triton X-100 buer. Mitochondria were isolated in mito-buer as described in`Materials and methods'. Twenty mg of cytosolic proteins and 5 mg of mitochondrial proteins were separated on 4 ± 20% gradient SDS ± PAGE, blotted to nitrocellulose membrane, blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20 and then incubated with mouse anti-Bcl-2 antibody. The blots were counterstained with antimouse IgG conjugated with HRP. The immunoreactive bands were visualized by incubation of the membrane with an enhanced chemiluminescence reagent. (b) PC3-Bcl-2 is resistant to treatment with TRAIL. Cells were plated at a density of 7000 cells/well in 96-well tissue culture¯at-bottom plates; TRAIL (at the indicated concentrations) was added at the time of plating and cell death was estimated 24 h later by calcein assay as described in`Materials and methods'. Each point represents mean values of seven separate experiments. In two experiments, cell death was estimated in PC3-Hygro in the presence of 10 mM of the pan-caspase inhibitor Z-VAD-fmk after treatment with 100 ng/ml of TRAIL (shown by column). Cell death was also estimated by crystal violet staining (data not shown), which gave similar results found that these caspases did not reside in mitochondria (data not shown). We then estimated caspase activity using Ac-DEVD-AMC as a substrate that is cleaved by dierent caspases. As shown in Figure 4 , caspase activity was found to be slightly lower in PC3-Bcl-2 compared to PC3-Hygro after 1 h of treatment with TRAIL, but after 4 h caspase activity in PC3-Hygro was four times higher than in PC3-Bcl-2. These data suggest that the higher molecular weight form of processed caspase-3 is inactive and only the fully processed form is active.
Caspases -2, -7, and -9 reside both in the cytosol and mitochondria and their activation is inhibited by Bcl-2 overexpression
We next investigated activation of caspases -2, -7, and -9 under TRAIL treatment of PC3-Hygro and PC3-Bcl-2 ( Figure 5 ) and found distinct patterns of expression and activation of these caspases compared to caspases -8 and -3. First, caspases -2, -7, and -9 were found both in the cytosol and in mitochondria. An additional dierence between these two groups of caspases (caspases -8 and -3 versus caspases -2, -7, and -9) is the time course of activation. Caspase-2 was activated in the cytosol of PC3-Hygro after 1 h of treatment and activated in mitochondria after 4 h of treatment, although the level of proenzyme was decreased in mitochondria after 1 h of treatment with TRAIL ( Figure 5 ). At the same time, caspase-2 activation in PC3-Bcl-2 was found to be dramatically lower in the cytosol and was not activated in mitochondria. The activation pattern between PC3-Hygro and PC3-Bcl-2 with caspase-7 showed only qualitative dierences. Caspase-7 was activated in the cytosol of PC3-Hygro after 4 h of treatment with TRAIL and activated after 1 h of treatment in mitochondria. However, we did not ®nd caspase-7 activation in PC3-Bcl-2 either in the cytosol or mitochondria. The dierences between PC3-Hygro and PC3-Bcl-2 of caspase-9 activation resembled caspase-2 expression: there were quantitative dierences in the cytosol and qualitative dierences in mitochondria. Taken together, these data clearly indicate that activation of caspases -2, -7, and -9 are Bcl-2-dependent.
Figure 2 PARP and DFF45 proteolysis is prevented in PC3-Bcl-2 during TRAIL-mediated apoptosis. Cells were treated with TRAIL (500 ng/ml) for 2 and 4 h. To isolate nuclear and cytosolic proteins, cells were gently lysed in a Dounce homogenizer with Te¯on pestle in ice-cold Mito-buer containing 250 mM of sucrose. Homogenates were spun at 16 000 g for 20 min at 48C and supernatants were used as mitochondria-free cytosol for assessment of DFF45. Pellets containing nuclei were layered over 30% sucrose in Nuclei buer and pelleted by centrifugation at 800 g for 10 min. Nuclei were lysed in sample buer for assessment of PARP. Twenty mg of nuclear or cytosolic proteins were separated on 4 ± 20% gradient SDS ± PAGE and expression of PARP and DFF45 was examined by Western blot analysis Figure 3 Bcl-2 overexpression does not aect the activation of caspase-8 but results in underprocessing of caspase-3. Cells were treated with TRAIL (500 ng/ml) for indicated times and expression of caspases -8 and -3 was examined by Western blot analysis as described in legend to Figure 1 . Both caspases were not found in mitochondria (data not shown). The arrow indicates the activated p20 subunit of caspases -8 and -3 Figure 4 Caspase activity is lower in PC3-Bcl-2 compared to PC3-Hygro after treatment with TRAIL. Caspase activity was estimated with Ac-DEVD-AMC, a substrate that is cleaved by several caspases. Cells were treated with TRAIL (500 ng/ml) for 1 and 4 h, harvested, lysed in KPM buer and assayed as described in`Materials and methods'. Measurements were calibrated against a standard curve of 7-amino-4-methylcoumarine (AMC), and data were expressed in nM of released AMC per mg of proteins Bcl-2 dependent apoptosis in prostate cancer OW Rokhlin et al
TRAIL-induced mitochondrial events are Bcl-2-dependent
We subsequently investigated whether Bcl-2 regulates TRAIL-induced apoptosis by blocking dissipation of DC m and cytochrome c release from mitochondria. Dissipation of DC m as measure by DiOC6¯uorescence was prevented by Bcl-2 (Figure 6c ). In addition, Bcl-2 completely blocked cytochrome c release in PC3-Bcl-2 ( Figure 6a ). It is noteworthy that cytochrome c release was already observed after 20 min of TRAIL treatment in sensitive cells. This indicates that cytochrome c release from mitochondria into the cytosol is one of the early events in TRAIL-induced apoptosis in PC3.
In separate experiments, we have found that the pancaspase inhibitor Z-VAD-fmk inhibited cytochrome c release (data not shown) and therefore conclude that TRAIL-induced cytochrome c release is caspasedependent. We have also investigated Bid processing, the Bcl-2 family member that has been described as being cleaved by caspase-8 and then triggering cytochrome c release Luo et al., 1998; Yamada et al., 1999) . As shown in Figure 7 , Bid processing is caspase-dependent and occurred at similar levels in PC3-Hygro and PC3-Bcl-2. These data are consistent with the pattern of caspase-8 activation which has been found to be the same in both cell lines. It appears that Bcl-2 acts downstream of Bid and Bcl-2 overexpression blocks the activity of processed Bid and prevents disruption of DC m and cytochrome c release.
FADD-DN inhibits TRAIL-mediated apoptosis
Based on the results described above, it became evident that Bcl-2 can protect PC3 cell death under TRAIL treatment without inhibiting caspase-8. This observation may be interpreted to mean that activation of caspase-8 is not sucient for apoptosis following TRAIL treatment. Alternatively, it may indicate that the downstream eect(s) of this caspase could be mediated (ampli®ed) by mitochondrial pathways and that an ampli®cation loop and cross-talk between cytosolic caspases (-8 and -3) and mitochondrial caspases (-2, -7, -9) can occur via Bid. To test this hypothesis, we overexpressed FADD-DN in PC3. Figure 8 shows that PC3-FADD-DN was resistant to TRAIL-mediated cell death. We then examined the activation of caspases and proteolysis of Bid, DFF45 and PARP. As can be seen from Figure 9 , FADD-DN prevented processing of caspase-8 and all other caspases tested as well as cleavage of Bid, DFF45 and PARP. These data indicate that activation of caspase-8 is necessary but not sucient in TRAIL-induced apoptosis, and cell death can occur only when the mitochondrial pathway remains intact. Overexpression of Bcl-2 blocks the mitochondria presumably by overriding the eect of Bid and prevents cell death under TRAIL treatment. In summary, TRAIL can not bypass the mitochondrial pathway in the human prostatic carcinoma cell line PC3 as has been observed in lymphoid cells (Walczak et al., 2000; Keogh et al., 2000) . Figure 5 Bcl-2 inhibits the activation of caspases -9, -7, and -2 both in the cytosol and mitochondria. Cells were treated with TRAIL (500 ng/ml) for indicated times; 20 mg of cytosolic and 5 mg of mitochondrial proteins were separated on 5 ± 20% SDS ± PAGE and expression of caspases -9, -7 and -2 was examined by Western blot analysis Oncogene Bcl-2 dependent apoptosis in prostate cancer OW Rokhlin et al
Discussion
Two dierent cell types have been identi®ed by investigating CD95 (Fas receptor) signaling pathways (Scadi et al., 1998; . In type I cells, activation of caspases -8 and -3 occurs prior to the loss of DC m , Bcl-2 overexpression does not block caspases -8 and -3 activation, and apoptosis is independent of mitochondrial activity. In type II cells, activation of caspases -8 and -3 occurs after the loss of DC m , Bcl-2 overexpression blocks caspases -8 and -3 activation, and apoptosis is dependent of mitochondrial activity. Thus, only in type II cells does activation of caspases -8 and -3 occur at a level downstream of mitochondria, depend on mitochondrial release of cytochrome c and apoptosis is inhibited by Bcl-2 overexpression. Since it has been shown that TRAIL recruits FADD and caspase-8 to TRAIL-R1 and -R2 it is presumed that it utilizes a pathway similar to the one used by Fas receptor (Sprick et al., 2000; Kischkel et al., 2000) , and it is reasonable therefore to apply the idea of type I and II cells to TRAIL-mediated apoptosis.
We noted caspase-8 activation after 20 min of treatment with TRAIL and caspase-3 activation after 1 h of treatment in PC3 cells. We also noted caspasedependent cytochrome c release from mitochondria after 20 min of treatment. At the same time, the loss of DC m was observed after 2 h of treatment with TRAIL. These data indicate that activation of caspases -8 and -3 occurs prior to the loss of DC m which is characteristic of type I cells. We also compared the Figure 6 (a,b) Bcl-2 prevents TRAIL-dependent cytochrome c release from mitochondria into the cytosol. PC3-Hygro and PC3-Bcl-2 were treated with TRAIL (500 ng/ml) for 20 min, 1 and 4 h. Cells were gently lysed in a Dounce homogenizer with a Te¯on pestle in ice-cold Mito-buer containing 250 mM of sucrose, and homogenates were spun at 800 g for 20 min at 48C. The supernatants were then spun at 16 000 g for 20 min and used as mitochondria-free cytosol. Pellets containing mitochondria were washed twice with Mito-buer and were lysed by TNC buer. Twenty mg of cytosolic and 5 mg of mitochondrial proteins were separated on 4 ± 20% SDS ± PAGE and expression of cytochrome c (a) and cytochrome oxidase (subunit II) (b) was examined by Western blot analysis. The absence of cytochrome oxidase in cytosol indicated that cytosol was not contaminated by mitochondria. (c) Disruption of mitochondrial transmembrane potential (DC m ) after treatment with TRAIL occurs in PC3-Hygro but not in PC3-Bcl-2. Cells were treated for indicated periods of times with TRAIL (100 ng/ml), then incubated for 45 min at 378C with 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)) (40 nM), washed twice with PBS and live cells were analysed in a FACS Vantage cyto¯uorometer (Becton Dickinson). The percentage of cells with low DC m is shown Figure 7 Bid processing is similar in PC3-Hygro and PC3-Bcl-2. Cells were treated with TRAIL (500 ng/ml) for indicated times, and mitochondria-free cytosol was prepared as described iǹ Materials and methods'. The eect of the pan-caspase inhibitor Z-VAD-fmk (100 mM) on the processing of Bid was also examined. Twenty mg of cytosolic protein were separated by 4 ± 20% SDS ± PAGE, and Bid expression was examined by Western blot analysis Figure 8 PC3-FADD-DN is resistant to treatment with TRAIL. Cells were plated at a density of 7000 cells/well in 96-well tissue culture¯at-bottom plates; TRAIL at indicated concentrations was added at the time of plating and cell death was estimated 48 h later by calcein assay as described in`Materials and methods'. Each point represents mean values of six replicates in one of three separate experiments, which gave similar results activation pattern of caspase-8 between control PC3 (PC3-Hygro) and PC3 overexpressing Bcl-2 and did not ®nd any dierences between them indicating that activation of caspase-8 is Bcl-2 independent; this is another feature of type I cells. However, in the case of PC3-Bcl-2, caspase-3 was found to be underprocessed after 4 h of treatment with TRAIL. The pattern of activation of caspases -2, -7, and -9 cannot be attributed to type I cells. First, in contrast to caspase-8, these caspases were found not only in the cytosol but also in mitochondria. Second, overexpression of Bcl-2 blocked activation of caspases -2, -7, and -9 as well as the loss of DC m and cytochrome c. Since in PC3-Bcl-2 activation of caspases -2, -7, and -9 was blocked, it is conceivable that one of these caspases or a combination of some of them is required to fully process caspase-3. These data suggest that caspase-8 alone cannot activate caspase-3 to full extent and as a result PARP and DFF45 were not cleaved in PC3-Bcl-2. Therefore, TRAIL-mediated apoptosis in PC3 is dependent on the disruption of mitochondria with release of cytochrome c and activation of caspase-9. This pathway is blocked by Bcl-2 which appears to act biochemically downstream of the processing of caspase-8. Consistent with this interpretation, Bid was found to be cleaved in PC3 and this could not be blocked by Bcl-2. Thus, apoptosis in PC3 following TRAIL treatment has characteristics of both type I and type II pathways.
Mitochondrial localization of caspases has previously been found in dierent cell types (Susin et al., 1999; Zhivotovsky et al., 1999; Mancini et al., 1998 Mancini et al., , 2000 and it was concluded that caspases with overlapping substrate speci®city may cleave speci®c substrates in dierent cellular compartments (Chandler et al., 1998) . The role of Bcl-2 in TRAIL-mediated apoptosis has been mainly investigated in lymphoid cells Keogh et al., 2000) . Bcl-2, a mammalian homologue of CED-9 in C. elegans, prevents cell death induced by a number of dierent agents (reviewed by Yang and Korsmeyer, 1996) . Bcl-2 was found to be associated with the outer (Bay et al., 1993) as well as with the inner (Gotow et al., 2000) mitochondrial membranes. Bcl-2 is considered to be a multifunctional protein (Reed, 1997) and one of its important anti-apoptotic functions is to block the loss of mitochondrial membrane potential (Shimizu et al., 1996) and the release of cytochrome c into the cytosol (Zamzami et al., 1996) . Cytochrome c released from mitochondria forms a complex (apoptosome) with Apaf-1 and procaspase-9, resulting in the activation of caspase-9 (Green and Reed, 1998) . Activated caspase-9 can in turn activate executioner caspases (-3, -6, -7) which result in a positive feedback between caspase activation and cytochrome c release from mitochondria (Green and Reed, 1998; Green and Kroemer, 1998) . Bcl-2 levels are known to be elevated in a broad range of tumors, indicating that Bcl-2 likely plays a role in resistance to chemotherapeutic treatment and provides a rationale for TRAIL to be used for treatment of chemoresistant tumors (Nicholson, 2000) .
In contrast to ®ndings in lymphoid cells, our study clearly shows that the human prostatic carcinoma cell line PC3 was eectively protected from TRAILmediated apoptosis by overexpression of Bcl-2. The importance of mitochondrial localization of caspases was observed during TRAIL-mediated apoptosis in PC3 and it is conceivable that control of apoptosis by Bcl-2 can occur by preventing activation of mitochondrial localized caspases -2, -7, and -9. We observed that overexpression of Bcl-2 almost completely inhibited the activation of these caspases and resulted in underprocessing of caspase-3 whereas activation of caspase-8 was unaected. These data indicate that activation of caspase-8 is insucient to complete apoptosis without involvement of mitochondrial localized caspases. We also found caspases -2, -7, and -9 in mitochondria both in untreated and apoptotic cells and therefore we cannot estimate whether translocation of caspases from the cytosol to mitochondria or vice versa occurs during apoptosis. Using PC3-FADD-DN, we have also observed that activation of caspase-8 is necessary but not sucient for TRAIL-mediated apoptosis since Bcl-2 blocks the mitochondria by overriding the eect of Bid and prevents cell death under TRAIL treatment. Therefore, TRAIL cannot bypass the mitochondrial pathway in PC3 as it has been observed in lymphoid cells.
While it has been suggested Keogh et al., 2000; Bonavida et al., 1999; that TRAIL can be used as an antitumor agent against Bcl-2-overexpressing lymphoid tumors, this conclusion might only be valid for lymphoid tumors. It does not appear to be a general rule. Our study clearly shows that the epithelial cell line PC3 was eectively protected from TRAIL-mediated apoptosis by Bcl-2 overexpression. Other appropriate therapeutic treatment need to be established for solid tumors that overexpress Bcl-2. Figure 9 FADD-DN prevents activation of caspases -2, -3, -7, -8, -9, inhibited Bid processing and proteolysis of DFF45 and PARP. PC3-mock (#1) and PC3-FADD-DN (#2) were treated with TRAIL (500 ng/ml) for 2 h. Expression of proteins was examined by Western blot analysis as described in legend to Figure 1 
Materials and methods
Cell lines and transfection
The human prostatic carcinoma cell line PC3 was cultured in RPMI 1640 as has been previously described (Rokhlin et al., 1997) . PC3 was transfected with the plasmid pSFFV-Hygro with or without cDNA encoding Bcl-2 followed by hygromycin selection. A dominant-negative form of FADD (FADD-DN) was made with PCR primers (5'-CCAAGCT-TATGGACGACTTCGAGGCGGGG and 5'-AAGGATC-CACCAGCGCAAAGCAGCGGCC)¯anking the region encoding 117 ± 208 aa and using the FADD cDNA as template. This region contains the DD but does not contain the death-eector domain (DED) (Chinnaiyan et al., 1995; Peter et al., 1996) . The HindIII/BamHI restriction sites were used for cloning FADD-DN into the expression vector pcDNA3.1/Hygro (Invitrogen, Carlsbad, CA, USA). Gene-PORTER reagent kit (Gene Therapy Systems) was used for transfection and cells were selected in the presence of hygromycin. Empty vector was used to obtain control cells resistant to hygromycin (PC3-mock). Human TRAIL was purchased from PeptoTech (Rocky Hill, NJ, USA).
Estimation of cells viability
To measure cell viability, we used calcein AM (Molecular Probes, Eugene, OR, USA). Calcein AM is a¯uorogenic esterase substrate that is hydrolyzed in live cells to a green uorescent product (calcein) and¯uorescence at 485/530 nm was measured with a FL600¯uorimeter (Bio-Tek Instruments, Inc., Burlington, VT, USA). Cells were incubated and treated in 96-well¯at-bottomed plates. After incubation, medium was removed, the plates were washed with PBS, and incubated with 100 ml of 2 mg/ml calcein AM solution for 30 min at room temperature. Fluorescence, which is proportional to cell viability, was then measured with FL600 uorimeter. Cell viability was also measured by crystal violet staining. In this case, cells (30 000/well/2 ml) were incubated and treated in 24-well plates. After treatment, 1 ml medium was removed and 750 ml of crystal violet solution (0.1% crystal violet, 2.1% citric acid in water) was added for 60 min at room temperature. Cells were washed three times with water and SDS solution (1%) was added to each well. Absorbance was measured using an ELISA plate reader at 630 nm. In both assays, TRAIL in various concentrations was added at the time of plating.
Assessment of apoptosis
Apoptosis was estimated by several methods: DNA laddering, caspase activation using both¯uorogenic substrates and Western blot analysis of activated caspases, and proteolysis of PARP and DFF-45 (Rokhlin et al., 1997 . For DNA laddering, cells were ®xed in 70% ethanol for 24 h at 7208C and DNA was extracted with 0.2 M phosphate-citrate buer at pH 7.8 as described . Under these conditions, the partially degraded, oligonucleosomal DNA is extracted quite selectively from the cells whereas the higher molecular weight DNA remains associated with the nuclei. The extracts were then treated with RNase A (1 mg/ml) in the presence of 0.25% NP-40 for 30 min at 378C, and then with proteinase K (1 mg/ml) for 30 min at 378C. The DNA was analysed on 1.5% agarose gel (at 4 V/cm) containing 0.5 mg/ml ethidium bromide. In order to measure caspase activity with¯uorogenic substrates, cytosolic extracts were prepared as described (Rokhlin et al., 1998) by repeated freezing and thawing of cells in KPM buer (50 mM PIPES, pH 7.0, 50 mM KCl, 1 mM EGTA, 2 mM MgCl 2 , 1 mM DTT, 10 mg/ml cytochalasin B, 0.1 mM PMSF, and 2 mg/ml pepstatin, leupeptin, and antipain). Forty mg of protein lysate was incubated at room temperature for 30 min in assay buer (20 mM PIPES, pH 7.2, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS and 10% sucrose) with 20 mM uorescent substrate-Ac-DEVD-AMC. Fluorescence at 360/ 460 nm was measured with a FL600¯uorimeter. Measurements were calibrated against a standard curve of 7-amino-4-methilcoumarin (AMC) (Sigma) and data were expressed in nM of released AMC per mg of cytoplasmic extract proteins. Western blot detection of proteins was performed as described previously (Rokhlin et al., 1997) . Brie¯y, 5 ± 20 mg of proteins were separated on 4 ± 20% gradient SDS ± PAGE, and blotted to nitrocellulose membrane (Novex, San Diego, CA, USA). Equal loading was controlled routinely by reversible staining of the membrane with Ponceau S solution (Sigma, St. Louis, MO, USA). Membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20 and then incubated with the corresponding mouse monoclonal or rabbit polyclonal antibodies: anti-cytochrome c, anti-PARP, anti-Bcl-2 (Pharmingen, San Diego, CA, USA), cytochrome oxidase (subunit II) (Molecular probes), anti-caspase 3 (Transduction Laboratories, San Diego, CA, USA), anticaspase-2, anti-Bid (R&D Systems, Minneapolis, MN, USA), anti-DFF45, anti-caspase-8, anti-FADD (Upstate, Lake Placid, NY, USA), anti-caspase-7 and anti-caspase-9 (Oncogene, Uniondale, NY, USA). The blots were counterstained with goat antimouse or antirabbit IgG conjugated with HRP (Pierce, Rockford, IL, USA). The immunoreactive bands were visualized by incubation of the membrane with enhanced chemiluminescence reagent (Pierce).
Detection of cytochrome c release and disruption of the mitochondrial transmembrane potential (DC m )
To detect cytochrome c release, mitochondria-free cytosol was prepared as described (Yang et al., 1997) . Brie¯y, cells were lysed in ice cold Mito-buer (20 mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 250 mM sucrose, 0.1 mM PMSF, 2 mg/ml pepstatin, leupeptin, and aprotinin) by homogenization in a small glass homogenizer with te¯on pestle (50 strokes on ice). The homogenates were ®rst spun at 800 g to remove nuclei and cell debris, then spun at 16 000 g for 20 min at 48C twice to pellet the mitochondria, and the supernatants were used for anti-cytochrome c Western blot analysis. Pelleted mitochondria were washed twice with Mito-buer and lysed in TNC buer (10 mM Tris-acetate, pH 8.0, 0.5% NP-40, 5 mM CaCl 2 , 1 mM DTT, 0.1 mM PMSF, 2 mg/ml pepstatin, leupeptin, and aprotinin) on ice for 15 min and then used for Western blot analysis. To investigate the disruption of DC m , we used 40 nM 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)) (Molecular Probes). Cells were treated for 1, 2, 3 and 4 h with TRAIL (500 ng/ml), then incubated for 30 min at 378C in complete media with DiOC6, washed twice with PBS and analysed in FACS Vantage cyto¯uorometer (Becton Dickinson).
